Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies
dc.contributor.author | Seefeldt, K. | en_US |
dc.contributor.author | Miller, J. | en_US |
dc.contributor.author | Alvarez-Núñez, F. | en_US |
dc.contributor.author | Rodríguez-Hornedo, N. | en_US |
dc.date.accessioned | 2007-09-20T18:25:41Z | |
dc.date.available | 2008-09-08T14:25:13Z | en_US |
dc.date.issued | 2007-05 | en_US |
dc.identifier.citation | Seefeldt, K.; Miller, J.; Alvarez-NÚÑez, F.; RodrÍguez-Hornedo, N. (2007)."Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies." Journal of Pharmaceutical Sciences 96(5): 1147-1158. <http://hdl.handle.net/2027.42/55996> | en_US |
dc.identifier.issn | 0022-3549 | en_US |
dc.identifier.issn | 1520-6017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55996 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17455346&dopt=citation | en_US |
dc.description.abstract | The work presented here was motivated by the premise that the amorphous state serves as a medium to study cocrystal formation. The molecular mobility inherent to amorphous phases can lead to molecular associations between different components such that a single crystalline phase of multiple components or cocrystal is formed. Cocrystallization pathways and kinetics were investigated from amorphous equimolar phases of carbamazepine and nicotinamide using hot-stage polarized microscopy (HSPM), hot-stage Raman microscopy (HSRM), differential scanning calorimetry (DSC), and X-ray powder diffraction (XRPD). Nonisothermal studies revealed that amorphous phases generate cocrystals and that thermal history affects crystallization pathways in significant ways. Two different pathways to cocrystal formation from the amorphous phase were identified: (1) at low heating rates (3°C/min) a metastable cocrystalline phase initially nucleates and transforms to the more stable cocrystalline phase of CBZ–NCT, and (2) at higher heating rates (10°C/min) individual components crystallize, then melt and the stable cocrystalline phase nucleates and grows from the melt. Isothermal studies above the T g of the amorphous equimolar phase also confirm the nucleation of a metastable cocrystalline phase from the amorphous state followed by a solid phase mediated transformation to the stable cocrystalline phase. Cocrystallization kinetics were measured by image analysis and by thermal analysis from small samples and are described by the Avrami–Erofeev model. These findings have important implications for the use of amorphous phases in the discovery of cocrystals and to determine the propensity of cocrystallization from process-induced amorphization. © 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 96: 1147–1158, 2007 | en_US |
dc.format.extent | 463430 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Chemistry | en_US |
dc.subject.other | Food Science, Agricultural, Medicinal and Pharmaceutical Chemistry | en_US |
dc.title | Crystallization pathways and kinetics of carbamazepine–nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmaceutical Sciences, 428 Church St. University of Michigan, Ann Arbor, Michigan 48109-1065 ; Chemical and Physical Sciences, Schering Plough Research Institute, Summit, New Jersey | en_US |
dc.contributor.affiliationum | Department of Pharmaceutical Sciences, 428 Church St. University of Michigan, Ann Arbor, Michigan 48109-1065 | en_US |
dc.contributor.affiliationum | Department of Pharmaceutical Sciences, 428 Church St. University of Michigan, Ann Arbor, Michigan 48109-1065 ; Department of Pharmaceutical Sciences, 428 Church St. University of Michigan, Ann Arbor, Michigan 48109-1065. Telephone: 734-763-0101; Fax: 734-615-6162 | en_US |
dc.contributor.affiliationother | Small Molecule Pharmaceutics, Amgen, Thousand Oaks, California | en_US |
dc.identifier.pmid | 17455346 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55996/1/20945_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/jps.20945 | en_US |
dc.identifier.source | Journal of Pharmaceutical Sciences | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.